Zoetis Inc. (NYSE:ZTS) Shares Acquired by PFG Advisors

PFG Advisors increased its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 28.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,627 shares of the company's stock after buying an additional 2,157 shares during the period. PFG Advisors' holdings in Zoetis were worth $1,585,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of ZTS. Obermeyer Wealth Partners increased its position in Zoetis by 11.3% during the first quarter. Obermeyer Wealth Partners now owns 1,932 shares of the company's stock worth $318,000 after purchasing an additional 196 shares during the last quarter. Regency Capital Management Inc. DE acquired a new position in Zoetis during the first quarter worth approximately $937,000. Peterson Wealth Services grew its stake in Zoetis by 13.7% during the first quarter. Peterson Wealth Services now owns 19,093 shares of the company's stock worth $3,144,000 after buying an additional 2,302 shares during the period. William Allan Corp grew its stake in Zoetis by 16.3% during the first quarter. William Allan Corp now owns 17,915 shares of the company's stock worth $2,950,000 after buying an additional 2,505 shares during the period. Finally, Wealth Alliance LLC grew its stake in Zoetis by 8.3% during the first quarter. Wealth Alliance LLC now owns 13,565 shares of the company's stock worth $2,233,000 after buying an additional 1,041 shares during the period. Institutional investors and hedge funds own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. UBS Group decreased their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Finally, Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $204.63.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.18% of the company's stock.

Zoetis Stock Down 0.6%

ZTS traded down $0.90 during trading on Friday, hitting $151.92. The company had a trading volume of 3,326,080 shares, compared to its average volume of 2,967,721. The company has a market cap of $67.64 billion, a PE ratio of 27.28, a P/E/G ratio of 2.53 and a beta of 0.91. The business has a 50-day moving average of $159.91 and a 200-day moving average of $161.01. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to analysts' expectations of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 earnings per share. As a group, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.32%. Zoetis's dividend payout ratio (DPR) is 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.